Navigation Links
Pioneer Award recipients Robin Ali, Ph.D., Jean Bennett, M.D., Ph.D., and William Hauswirth, Ph.D.
Date:9/3/2014

New Rochelle, NY, September 3, 2014Robin Ali, PhD, University College London, Jean Bennett, MD, PhD, Perelman School of Medicine, University of Pennsylvania, and William Hauswirth, PhD, University of Florida College of Medicine, are co-recipients of the Pioneer Award, recognized for their leadership and contributions to the field of gene therapy to treat retinal degeneration leading to blindness. Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, is commemorating its 25th anniversary by bestowing this honor on the leading Pioneers in the field of cell and gene therapy selected by a blue ribbon panel* and publishing a Pioneer Perspective by the award recipients.

Dr. Ali, Professor of Human Molecular Genetics, led proof-of-concept studies demonstrating the feasibility of using gene therapy to repair photoreceptor defects in the eye and of using cell transplantation for retinal repair. He also had a pioneering role in the first clinical trial for inherited retinal degeneration.

Dr. Bennett, Professor of Ophthalmology, Cell and Developmental Biology, recalls her first experiences with molecular biology and gene transfer technology, acquired in the lab of Dr. W. French Anderson, known as "the father of gene therapy." She describes her developing career, including the decision to go to medical school and to focus her research on developing adeno-associated virus (AAV) gene therapy techniques for restoring vision to patients affected by retinal degeneration in her Pioneer Perspective article entitled "My Career Path for Developing Gene Therapy for Blinding Diseases: The Importance of Mentors, Collaborators, and Opportunities," available on the Human Gene Therapy website.

Dr. Hauswirth, Rybaczki-Bullard Professor of Ophthalmology, traces his involvement in the field of retinal gene therapy to his early interest in studying the interaction between light and biological molecules. He provides a historical perspective on the discovery of the gene mutations responsible for several of the most common inherited eye diseases and the advances in AAV gene therapy technology being developed and applied to deliver replacement genes. His Pioneer Perspective, entitled "Retinal Gene Therapy Using Adeno-Associated Viral Vectors: Multiple Applications for a Small Virus," is available on the Human Gene Therapy website.

"These groups brought forward the first convincing clinical results of in vivo gene therapy, which paved the way for the current renaissance we are seeing in the field," says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.


'/>"/>

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground
2. Pioneer in next generation sequencing receives 2014 HudsonAlpha Life Sciences Prize
3. Christof von Kalle, M.D., Ph.D. receives Pioneer Award
4. Frederic Bushman, Ph.D. receives Pioneer Award for advancing therapeutic gene delivery methods
5. NJIT researchers probe links between vision problems and cognition in a pioneering study
6. Celebrating the work of a neglected scientific pioneer
7. Pioneering forensics research into body fluids in sexual assaults
8. James Wilson, M.D., Ph.D. receives Pioneer Award
9. Pioneering findings on the dual role of carbon dioxide in photosynthesis
10. Why didnt these pioneers of medicine receive a Nobel Prize?
11. Pioneer Award recipients Marina Cavazzana and Adrian Thrasher recognized for advancing gene therapy to the clinic for immunodeficiency disorders
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Pioneer Award recipients Robin Ali, Ph.D., Jean Bennett, M.D., Ph.D., and William Hauswirth, Ph.D.
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
(Date:3/22/2017)... YORK , March 21, 2017 ... Marketing Cloud used by retailers such as 1-800-Flowers ... its platform — Product Recommendations and Replenishment. Using Optimove,s ... give more personalized product and replenishment recommendations to ... but also on predictions of customer intent drawn ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... For today, Stock-Callers.com redirects investors, attention to Biotechnology, ... research aimed at treating diseases and medical conditions. Under evaluation ... (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), and ZIOPHARM Oncology ... complimentary research reports on these stocks now at: ... http://stock-callers.com/registration Biostage ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics ... Company Seeks to Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial ... an 81 patient clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in ...
(Date:4/19/2017)... Calif. , April 19, 2017  As ... Drug Abuse and Heroin Summit ,  Proove® Biosciences, ... study analyzing genetics, environmental, and lifestyle factors to ... from the University of Southern California (USC), the ... , and Proove publish results showing that Proove ...
(Date:4/18/2017)... ... April 18, 2017 , ... ... Channel Partners 2017 Next-Gen Solution Provider. , Channel Partners program recognizes IT and ... their vision, innovation, and advocacy of the channel during transition and convergence. CallTower ...
Breaking Biology Technology: